STAT
DECEMBER 22, 2023
In ten years, the United States could be short as many as 48,000 primary care doctors. The specialty is underpaid, to a point that doctors are lobbying Medicare to pay it extra. Even medical residents who chose the specialty are leaving primary care ; some 45% of residents who planned to be generalists changed their mind during their residencies. But R.
PharmaVoice
DECEMBER 22, 2023
The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists. Still, the complexities of the disease and of drug development have brought hard-felt losses.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
DECEMBER 22, 2023
In the days leading up to Christmas in the pediatric intensive care unit (PICU), medical teams work to send as many children home as they can. Kids should be with their people for the holidays. And it makes sense. But for parents of children receiving in-home care — parents like me — it can be a relief to surrender to the hospital’s siren song.
ALiEM - Pharm Pearls
DECEMBER 22, 2023
An 84-year-old female presented with a chief complaint of right hip pain after a fall 12 hours prior to presentation. The patient reported a history of falls resulting in shoulder, rib, and left hip fractures in the past. The patient stated that upon getting out of bed, she took 4-5 steps, lost her balance, and fell backward onto the bedroom floor. She denied loss of consciousness.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
DECEMBER 22, 2023
As we enter the fifth year of this challenging decade, life finally appears to be inching toward normal — a new normal — on the infectious diseases front. Humans and the SARS-CoV-2 virus seem to be making progress toward a detente with each other. Covid is still a major disruptor, a significant cause of illness and death. But the massive disease waves of the early 2020s have calmed down.
LifeProNow
DECEMBER 22, 2023
December 14, 2023: “The U.S. District Court for the District of Massachusetts has entered a consent decree of permanent injunction ordering Pharmasol Corporation, a Massachusetts-based company, and President Marc L. Badia to stop distributing drugs until the company complies with the Federal Food, Drug, and Cosmetic (FD&C) Act and other requirements listed in the consent decree.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
LifeProNow
DECEMBER 22, 2023
December 20, 2023: “GSK plc and Hansoh Pharma, a Chinese biopharmaceutical company committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders” announced that they have entered into an exclusive license agreement for HS-20093, a B7-H3 targeted antibody-drug conjugate (ADC) utilising a clinically validated topoisomerase inhibitor (TOPOi) payload.
STAT
DECEMBER 22, 2023
WASHINGTON — Venture capitalists are still pouring money into drug research in spite of Medicare’s new power to negotiate drug prices, according to Congress’ nonpartisan budget experts. The Inflation Reduction Act includes two measures that directly lower drug prices. Medicare price negotiation is the most controversial of the two.
PharmaVoice
DECEMBER 22, 2023
A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.
STAT
DECEMBER 22, 2023
The Food and Drug Administration issued a change to the warning label for Legend Biotech and Janssen’s myeloma CAR-T, Carvykti or cilta-cel, adding that some secondary blood cancers have occurred following treatment for multiple myeloma with the cell therapy. While the label means that physicians will have to have a conversation about secondary malignancies occurring after Carvykti treatment, oncologists and CAR-T experts said the label update won’t change anything about the
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
European Pharmaceutical Review
DECEMBER 22, 2023
French pharmaceutical giant Sanofi announced that it is ending the development programme evaluating tusamitamab ravtansine as a monotherapy for certain patients with metastatic non-squamous, non-small cell lung cancer (NSCLC). The decision comes after interim analysis from a Phase III clinical trial , CARMEN-LC03, did not meet a primary end point. CARMEN-LC03, a randomised, open-label study was evaluating tusamitamab ravtansine as monotherapy compared to docetaxel in patients with metastatic non
STAT
DECEMBER 22, 2023
And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but we expect to promenade with the official mascots, catch up on our reading, and hang with a relative or two. We also hope to hold another listening party with Mrs.
PharmExec
DECEMBER 22, 2023
Oxford Academic report explores the positive improvements these technological capabilities could bring to the industry.
STAT
DECEMBER 22, 2023
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with the final edition of this newsletter for 2023. We’re taking a break for the holidays and will be back in your inbox bright and early on Jan. 3.
pharmaphorum
DECEMBER 22, 2023
This year brought about a whole gambit of news and developments, of conferences and launches, all coming in thick and fast and excited about the pharmaceutical industry and healthcare system. Not least of these was Smith + Nephew’s opening of a new state-of-the-art surgical innovation and training centre in the heart of Munich, Germany, on 11th October.
STAT
DECEMBER 22, 2023
Understand how science, health policy, and medicine shape the world everyday. Sign up for our Morning Rounds newsletter here. Health data breaches set a record this year “We’re writing to inform you of a cybersecurity incident”: If you’ve gotten a message like this from your health care organization, you’re not alone.
European Pharmaceutical Review
DECEMBER 22, 2023
Bristol Myers Squibb (BMS) has agreed to acquire Karuna Therapeutics for a total of $14.0 billion, strengthening its neuroscience portfolio. Under the terms of the deal, BMS will acquire all outstanding shares of Karuna Therapeutics common stock for $330.00 per share in cash. This represents a 53 percent premium on Karuna’s closing stock price on 21 December 2023.
Pharmaceutical Technology
DECEMBER 22, 2023
As the number of patients with cancers continues to grow globally, research into personalised cancer vaccines is vital.
European Pharmaceutical Review
DECEMBER 22, 2023
MeiraGTx has entered into an asset purchase agreement with Janssen Pharmaceuticals for the remaining interests in botaretigene sparoparvovec (bota-vec) a gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP). Under the agreement, MeiraGTx is to receive $130 million in upfront and near-term milestone payments. The company will receive up to an additional $285 million in cash payments upon first commercial sales of bota-vec in the US and EU, as well as for manufacturing technology
pharmaphorum
DECEMBER 22, 2023
AstraZeneca and Ionis get first approval for ATTR polyneuropathy drug Wainua (eplontersen), a rival to drugs from Alnylam and Pfizer
The Guardian - Pharmaceutical Industry
DECEMBER 22, 2023
Research carried out on pigs showed they ate almost 40% less food after ingesting the capsule Dieters everywhere know that, no matter how inventive a chef you may be, nothing leaves you buzzing like sugary or fatty food. Now science might have the answer: a vibrating pill, swallowed before eating, that creates feelings of fullness. Continue reading.
pharmaphorum
DECEMBER 22, 2023
Discover three key strategies to make 2024 the year of the patient in healthcare. Learn how revolutionising trial design, embracing technology, and breaking down silos can improve patient care and outcomes.
Express Pharma
DECEMBER 22, 2023
With this, the company enters the Indian liquid laxative market with this innovative product that is a formulation of Isabgol fibre in liquid form and natural actives such as Sonamukhi, Harad, Mulethi, Saunf, Amaltas and Gulab Dal LupinLife, the consumer healthcare business of Lupin has announced the launch of Softovac Liquifibre , Ayurvedic liquid laxative.
EMCrit Project
DECEMBER 22, 2023
Is your mind ready for no preparation critical care? EMCrit Project by Scott Weingart, MD FCCM.
pharmaphorum
DECEMBER 22, 2023
Discover how AI is transforming the healthcare industry by automating boring and mundane tasks, allowing healthcare professionals to focus on more interesting and important aspects of patient care.
BioPharma Dive
DECEMBER 22, 2023
The deal would hand Bristol Myers, which has newly made neuroscience a therapeutic focus, an experimental treatment for schizophrenia.
Drug Patent Watch
DECEMBER 22, 2023
Annual Drug Patent Expirations for NEXLIZET Nexlizet is a drug marketed by Esperion Theraps Inc and is included in one NDA. It is available from one supplier. There are ten… The post New patent expiration for Esperion Theraps drug NEXLIZET appeared first on DrugPatentWatch - Make Better Decisions.
BioPharma Dive
DECEMBER 22, 2023
The biotech is asking the agency to clear its treatment Elevidys in more patients with the disease, despite a confirmatory trial that missed its main goal.
Drug Patent Watch
DECEMBER 22, 2023
Annual Drug Patent Expirations for FINTEPLA Fintepla is a drug marketed by Ucb Inc and is included in one NDA. It is available from one supplier. There are twelve patents… The post New patent for Ucb Inc drug FINTEPLA appeared first on DrugPatentWatch - Make Better Decisions.
Pharmafile
DECEMBER 22, 2023
AstraZeneca and Ionis have announced that the US Food and Drug Administration (FDA) has approved Wainua (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hAATTR-PN or ATTRv-PN) in adult patients. The drug is the only approved treatment for this indication and can be self-administered with an auto-injector.
Drug Patent Watch
DECEMBER 22, 2023
Annual Drug Patent Expirations for AUSTEDO+XR Austedo Xr is a drug marketed by Teva and is included in one NDA. It is available from one supplier. There are nine patents… The post New patent for TEVA drug AUSTEDO XR appeared first on DrugPatentWatch - Make Better Decisions.
Pharmafile
DECEMBER 22, 2023
Calliditas Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobin A nephropathy (IgAN) at risk of disease progression. The drug was previously approved in December 2021 under the accelerated approval pathway, however this approval […] The post Calliditas Therapeutics gains FDA approval of Tarpeyo appeared first on Pharmafile.
Drug Patent Watch
DECEMBER 22, 2023
Annual Drug Patent Expirations for NEXLETOL Nexletol is a drug marketed by Esperion Theraps Inc and is included in one NDA. It is available from one supplier. There are eight… The post New patent expiration for Esperion Theraps drug NEXLETOL appeared first on DrugPatentWatch - Make Better Decisions.
BioPharma Dive
DECEMBER 22, 2023
The clearance of Wainua for transthyretin amyloidosis opens up a new front in a long-running commercial battle between Ionis and Alnylam.
Drug Patent Watch
DECEMBER 22, 2023
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and Teva and is included in two NDAs. It is available from one supplier. There… The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
334 
Let's personalize your content